MDM2 and breast carcinoma: The tissue-specific effects observed are also in line with the previously observed effect of the MDM2 SNP285G > C; where the C-allele is proposed to reduce the risk for ovarian, endometrial, and breast cancer, but not cancer of the prostate, lung, or colon [15, 28, 36, 37].